Filed on 2010-12-10 by Abbott Laboratories SEC CIK 1800 Form 4
Accession 0001104659-10-062171.txt Sec File: edgar/data/1800/0001104659-10-062171-index.htm
2010-10-28 Abbott Laboratories (CIK 1800) through Direct
Invested in Trubion Pharmaceuticals Inc sold 2243649 shares remaining shares owned 0
Common Stock Trubion Pharmaceuticals Inc Trbn Transaction code: J Other acquisition or disposition (transaction described in footnotes)
f1 this form 4 relates to shares of common stock, par value $0.001 of trubion pharmaceuticals, inc. ("trubion common stock"). on october 28, 2010, pursuant to an agreement and plan of merger dated august 12, 2010, as amended, by and among emergent biosolutions inc. ("emergent"), 35406 llc, a direct wholly-owned subsidiary of emergent, 30333 inc., an indirect wholly-owned subsidiary of emergent and trubion pharmaceuticals, inc. ("trubion"), emergent completed its acquisition of trubion (the "merger"). (continued in footnote 2)
f2 (continued from footnote 1) as a result of the merger each of the 2,243,649 shares of trubion common stock owned by abbott laboratories outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive: an amount in cash equal to $1.365; 0.1641 of a share of common stock of emergent; and one contingent value right, which entitles the holder thereof to receive a pro rata portion of certain contingent payments following the achievement of future development milestones under certain of trubion's collaboration agreements.
Filed on 2010-09-27 by Abbott Laboratories SEC CIK 1800 Form 3
Accession 0001104659-10-050054.txt Sec File: edgar/data/1800/0001104659-10-050054-index.htm
2010-09-27 Abbott Laboratories (CIK 1800) through Direct
Invested in Trubion Pharmaceuticals Inc remaining shares owned 2243649
Common Stock Trubion Pharmaceuticals Inc Trbn
f1 this form 3 relates to shares of common stock, par value $0.001 of trubion pharmaceuticals, inc. ("trubion common stock"). facet biotech corporation, a delaware corporation (the "company"), was acquired by abbott laboratories, an illinois corporation ("abbott"), pursuant to a transaction that was completed on april 21, 2010 (the "acquisition"). following the acquisition, the company's name was changed to abbott biotherapeutics corp. in connection with the integration of the company into abbott following the acquisition, on september 27, 2010, the company transferred beneficial ownership of all 2,243,649 shares of trubion common stock previously acquired by the company as reported on form 3 filed by the company on september 3, 2009, to abbott.